Physician profile
Jack Rush
NPI 1356399844
$2,146.71
in general payments reported to CMS, 2019-2025
21 companies · $25.68 in 2025
The $25.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $149 · 2021: $300 · 2022: $250 · 2023: $458 · 2024: $610 · 2025: $25.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $415.68 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $313.85 | 2019-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $203.66 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $200.69 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $146.20 | 2023-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $120.88 | 2019-2022 | |
| Edwards Lifesciences Corporation | $103.68 | 2021 | |
| Pfizer INC. | $87.32 | 2019-2023 | |
| Abbvie INC. | $79.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $78.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $71.62 | 2019-2022 | |
| Exact Sciences Corporation | $57.36 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.99 | 2019-2023 | Synjardy, Jardiance |
| Abbott Laboratories | $47.00 | 2022-2024 | Freestyle Libre 2 |
| Astellas Pharma US INC | $42.56 | 2024 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $27.87 | 2024 | Prolastin-C Liquid |
| Ferring Pharmaceuticals INC. | $26.03 | 2023 | Rebyota |
| Otsuka America Pharmaceutical, INC. | $25.68 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Dexcom, INC. | $15.88 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $15.24 | 2023 | Eliquis |
| Amarin Pharma, INC. | $15.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.